Hallett David 4

What Happened David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals (RXRX), had 11,908 shares withheld by the company to satisfy tax withholding obligations related to the net settlement of restricted stock units. The shares were valued at $3.49 each, for a total of about $41,559. This was a tax-withholding disposition (code F), not an open-market sale.

Key Details

• Transaction date: 2026-02-17; Filing date: 2026-02-19 (appears timely).
• Transaction type/code: Withholding to satisfy tax liability (F); reported as a disposition of 11,908 shares at $3.49/share (total ~$41,559).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: F1 — Issuer withheld shares to satisfy its tax withholding and remittance obligations in connection with net settlement of RSUs.

Context This was a routine tax-withholding event tied to RSU settlement (net settlement), meaning shares were retained by the company to cover taxes rather than sold on the open market by the insider. Such withholdings are common and do not necessarily indicate the insider's view of the company’s stock.